EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
    • EpiCC
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • High Throughput Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • Deimmunization
    • Trusted Expert Advice (TEA) Consulting Services
  • Lab Services
    • Lab Services Overview
    • HLA Binding Assays
    • T Cell Assays
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
    • Recipes For Success (Podcast)
  • Contact Us
Select Page
In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

by Riley Nolan | Oct 11, 2022

Addressing Immunogenicity of Observed and Theoretical Impurities for Peptide Abbreviated New Drug Applications

Addressing Immunogenicity of Observed and Theoretical Impurities for Peptide Abbreviated New Drug Applications

by Annie De Groot | Sep 23, 2020

Addressing Immunogenicity of Observed and Theoretical Impurities for Peptide Abbreviated New Drug Applications
Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS A Case Study of Taspoglutide

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS A Case Study of Taspoglutide

by Annie De Groot | Sep 9, 2019

EpiVax_PANDA_Taspoglutide_April_19_Final
Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics…of Peptides and P-ANDAS

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics…of Peptides and P-ANDAS

by Annie De Groot | Oct 30, 2018

EpiVax_EuroTIDES_PANDA_02Nov18 To learn more about EpiVax’s PANDA Program, read our latest entries. PANDA screening Interview with Brian Roberts: Protein Therapeutics Manager PANDA Press Release

Recent Posts

  • Artificial vs. Human Intelligence: The war of the worlds?
  • Providence-based “Biotech start up” EpiVax Celebrates 25th Anniversary
  • EpiVax: 25 years of Fearless Science
  • Looking Back and Moving Forward at 25
  • 2023 Amsterdam Immunogenicity & Tolerance Seminar

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Recipes for Success – Vlog
  • Thinking Out Loud -Blog
  • Uncategorized
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2023 EpiVax, Inc. – Informatics and Immunology, All rights reserved. Privacy Policy • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562